Publications

Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D et al..  2020.  Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.. Nat Commun. 11(1):1987.

Kaya C, Dorsaint P, Mercurio S, Campbell AM, Eng KWha, Nikiforova MN, Elemento O, Nikiforov YE, Sboner A.  2021.  Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples.. Thyroid. 31(4):589-595.

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 30(4):563-577.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JMiguel, Pauwels J, Park K, Kossai M et al..  2014.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.. Nat Commun. 5:5383.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..  2019.  Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Park K, Tran H, Eng KW, Ramazanoglu S, Rolon RMMarrero, Scognamiglio T, Borczuk A, Mosquera JMiguel, Pan Q, Sboner A et al..  2020.  Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.. Arch Pathol Lab Med.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.

Sboner A, Elemento O.  2016.  A primer on precision medicine informatics.. Brief Bioinform. 17(1):145-53.

Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Publisher Correction: Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1309.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Conteduca V, Ku S-Y, Puca L, Slade M, Fernandez L, Hess J, Bareja R, Vlachostergios PJ, Sigouros M, Mosquera JMiguel et al..  2020.  SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.. Mol Cancer Ther. 19(5):1157-1164.

Auguste A, Blanc-Durand F, Deloger M, Le Formal A, Bareja R, Wilkes DC, Richon C, Brunn B, Caron O, Devouassoux-Shisheboran M et al..  2020.  Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond Mutations: A Comprehensive Genomic Analysis.. Cells. 9(6)

Manohar J, Abedian S, Martini R, Kulm S, Salvatore M, Ho K, Christos P, Campion T, Imperato-McGinley J, Ibrahim S et al..  2021.  Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter.. medRxiv.

Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan LB, De Leon JPauline, Croyle JA, Kaner J et al..  2021.  Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia.. NPJ Precis Oncol. 5(1):44.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.